Mark Levis, MD, PhD, talks about new information about gilteritinib in FLT3 mutated acute myeloid leukemia (AML) at Annual Meeting 2018.
Gilteritinib in FLT3 mutated AML patients
Mark Levis, MD, PhD, talks about new information about gilteritinib in FLT3 mutated acute myeloid leukemia (AML) at Annual Meeting 2018.